Navigation Links
UNC researcher to help lead new esophageal cancer network
Date:10/7/2011

CHAPEL HILL, N.C. -- A University of North Carolina at Chapel Hill researcher is one of five co-principal investigators in a new collaborative network created to study genetic determinants of Barrett's esophagus and esophageal adenocarcinoma.

Nicholas J. Shaheen, MD, MPH, professor in the UNC School of Medicine, adjunct professor in the UNC Gillings School of Global Public Health and director of the UNC Center for Esophageal Diseases and Swallowing, will co-direct these Barrett's Esophagus Translational Research Network (BETRNet) projects. Shaheen is also a member of UNC Lineberger Comprehensive Cancer Center.

The BETRNet is funded by a $5.4 million grant from the National Institutes of Health. The other co-principal investigators of this BETRNet consortium are Dr. Amitabh Chak, professor of medicine at the Case Western Reserve University (CWRU) School of Medicine, Dr. Sanford Markowitz, Ingalls Professor of Cancer Genetics at the CWRU School of Medicine, Dr. Nathan A. Berger, Hanna-Payne Professor of Experimental Medicine at CWRU, Dr. Robert Elston, Professor of Epidemiology and Biostatistics at CWRU, and Dr. William Grady, Professor of Medicine at the University of Washington and Fred Hutchinson Cancer Research Center.

"Collaborations such as these between basic and translational scientists and clinical researchers will be essential to unravel the complex interplay between environmental and genetic influences on cancer development," said Shaheen.

Roy C. Orlando, MD, Mary Kay & Eugene Bozymski and Linda & William Heizer distinguished professor of gastroenterology and adjunct professor of cell and molecular physiology at UNC, is also a member of the BETRNet faculty.

Although the rate of many common cancers has declined in recent years, the rate of esophageal cancer has increased greater than six-fold over the past three decades. The prognosis for this cancer remains poor, accounting for over 1 in 50 adult male cancer-related deaths. Though Barrett's esophagus, a precursor of esophageal cancer, can be easily recognized at endoscopy, current medical strategies of performing endoscopy based on the close association of Barrett's with chronic heartburn in adults are very inadequate. Nearly 40 percent of patients who develop esophageal cancer have no preceding symptoms of heartburn, and most people with heartburn never have endoscopy. Less than 5 percent of cancers are diagnosed at an early stage in patients whose Barrett's was recognized prior to cancer diagnosis.

The BETRNet projects include discovery of genes that cause Barrett's esophagus to run in certain families, genes that become targets of DNA methylation in Barrett's and in esophageal cancers, and genes that are either turned on or turned off in Barrett's esophagus and in esophageal cancers. The overall aims of the network are to develop new methods of identifying individuals at risk for Barrett's esophagus, early detection of Barrett's and esophageal cancers, and monitoring Barrett's esophagus to recognize when it is likely to progress to cancer.


'/>"/>
Contact: Tom Hughes
tahughes@unch.unc.edu
919-966-6047
University of North Carolina School of Medicine
Source:Eurekalert  

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Tiny fruit fly could offer big clues in fight against obesity, researcher says
6. Researchers create drug to keep tumor growth switched off
7. MSU researcher linking breast cancer patients with alternative therapies
8. UT researcher receives $2.4 million to research obesity, high-risk pregnancy
9. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
10. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
11. Clemson researchers develop hands-free texting application
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UNC researcher to help lead new esophageal cancer network
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and ... Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD ... that can be easily incorporated into liquid products, while reducing costs to end users. ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
Breaking Medicine Technology: